Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study

Anavex Life Sciences Corp AVXL has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine).

  • Pre-treatment with blarcamesine repeated once daily for one week before the Aβ (Abeta) challenge was protective in the Aβ25-35 peptide model of Alzheimer's mice model. 
  • ANAVEX2-73 significantly and dose-dependently prevented Aβ25-35-induced biomarker-correlated cognitive impairments.
  • Data from this study will be submitted later this year for presentation at a scientific medical meeting.
  • An extension of the published study (ANAVEX2-73-003) demonstrated that for the same patients at week 70, cognition scores improved by +3.0, a 14% improvement from baseline.
  • In these same patients, ANAVEX2-73 also improved ADCS-ADL, by +6.0 points, an 8% mean improvement from baseline to 70 weeks. 
  • Price Action: AVXL shares are down 9.79% at $19.27 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralAlzheimer's diseaseBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!